Skip to main content

Table 1 Patient characteristics by anlotinib dose cohort

From: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Characteristic

Number of patients

Four consecutive weeks

2-week on/1-week off

5 mg/person

10 mg/person

10 mg/person

12 mg/person

16 mg/person

Total

 

4

4

3

21

3

 Sex

Male

2

2

2

15

1

Female

2

2

1

6

2

 Age, year

Median

39

50

60

47

45

Range

21–49

39–60

53–65

32–60

48–55

 ECOG score

0

0

1

0

9

0

1

4

3

3

12

3

 Pretreatment

Surgery

3

4

2

18

2

Radiotherapy

2

1

3

6

1

Chemotherapy

4

4

3

15

3

 Tumor site

Sarcoma

2

1

1

4

1

MTC

0

0

0

6

0

CC

1

2

0

0

1

NSCLC

0

0

1

3

0

RC

0

0

0

4

0

Other

1

1

1

4

1

  1. ECOG Eastern Cooperative Oncology Group, MTC medullary thyroid carcinoma, CC colorectal carcinoma, NSCLC non-small cell lung cancer, RC renal carcinoma